Conditions: Ovarian Cancer Basal Cell Carcinoma Metastatic Colorectal Cancer
Keywords: Hedgehog pathway inhibitor
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 19
Healthy volunteers: no

Brief summary:
This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent study closed were eligible for continued treatment in this protocol.

Detailed description:

Arms:
arm 1: Participants received 150 mg vismodegib orally once a day until disease progression, intolerable toxicity, or withdrawal from the study. If a participant had been receiving combination chemotherapy and/or biotherapy (FOLFOX, FOLFIRI, bevacizumab) in a parent study, the same combination chemotherapy and/or biotherapy as specified in the parent study could be continued in this study at the discretion of the investigator.

Interventions: intervention 1: Vismodegib intervention 2: FOLFOX intervention 3: FOLFIRI intervention 4: Bevacizumab
Intervention descriptions: intervention 1: Vismodegib was supplied in capsules. intervention 2: FOLFOX (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and oxaliplatin \[OX\]) was supplied as solutions for intravenous administration. intervention 3: FOLFIRI (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and irinotecan \[IRI\]) was supplied as solutions for intravenous administration. intervention 4: Bevacizumab was supplied as a solution for intravenous administration.

Protocol document: